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background: The ABSORB Cohort A trial results demonstrated the safety of the Absorb BVS (Abbott Vascular, Santa Clara, CA) in 30 patients with 
single de novo native coronary artery lesions, with a low long-term MACE rate at 5 years (3.4%). The ABSORB Cohort B trial, a continuation in that 
assessment with a modified Absorb, enrolled 101 patients at 12 sites in the European and Asia Pacific regions between March and November 2009.
Methods: The patients of the ABSORB Cohort B trial were divided into 2 groups, Group B1 (45 patients) having angiographic follow-up performed 
at 180 days and 2 years and Group B2 (56 patients) having angiographic follow-up performed at 1 and 3 years. Key clinical endpoints include 
ischemia driven MACE (ID-MACE) and its components at 30 days, 6, 9 and 18 months, and 1, 2, 3, 4 and 5 years.
results: In Cohort B, clinical data up to 3 years for the full cohort of 101 patients (Group B1 and B2) are currently available and showed an ID-
MACE rate of 10.0% (3 NQMI and 7 ID-TLR by PCI). Between 12 months and 3 years there were 2 ID-TLR events at 2 year follow up and one ID-TLR 
between 2 and 3 years. There were no scaffold thrombosis events up to 3 years.
conclusion: Three year clinical outcomes of ABSORB Cohort B showed that the device was safe. Four year clinical follow-up data on all 100 
patients will be presented.
